Clearside Biomedical Stock Crushes Shorts After Drug Data

It would take shorts more than a week to cover, at the average pace of trading

Mar 5, 2018 at 9:56 AM
facebook twitter linkedin


Shares of Clearside Biomedical Inc (NASDAQ:CLSD) are trading up 64.3% at $12.85 -- fresh off a 15-month high of $13.25, and on track for their biggest one-day gain ever. The drugmaker released positive topline data for its treatment on patients with macular edema associated with non-infectious uveitis, which is a build-up of fluid in the eye that negatively impacts vision.

Heading into today's trading, the shares had been chopping lower since topping $10 in late July, and hit a record low of $5.30 on Feb. 9. Short sellers, meanwhile, targeted CLSD stock during its recent technical troubles, with short interest surging 18.6% between the Feb. 1 and Feb. 15 reporting periods.

As such, it's likely a short squeeze is creating even bigger tailwinds for Clearside Biomedical shares. In fact, at the stock's average daily pace of trading, it would take more than a week to buy back these bearish bets.

Analysts, on the other hand, were already bullish on Clearside Biomedical, with all six covering analysts maintaining a "buy" or better rating. Plus, the average 12-month price target of $19.20 represented expected upside of nearly 146% to last Friday's close at $7.82.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners